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IMPORTANCE It is uncertain whether depressive symptoms are independently associated
with subsequent risk of cardiovascular diseases (CVDs).
OBJECTIVE To characterize the association between depressive symptoms and CVD incidence
across the spectrum of lower mood.
DESIGN, SETTING, AND PARTICIPANTS A pooled analysis of individual-participant data from the
Emerging Risk Factors Collaboration (ERFC; 162 036 participants; 21 cohorts; baseline
surveys, 1960-2008; latest follow-up, March 2020) and the UK Biobank (401 219
participants; baseline surveys, 2006-2010; latest follow-up, March 2020). Eligible
participants had information about self-reported depressive symptoms and no CVD history
at baseline.
EXPOSURES Depressive symptoms were recorded using validated instruments. ERFC scores
were harmonized across studies to a scale representative of the Center for Epidemiological
Studies Depression (CES-D) scale (range, 0-60; 16 indicates possible depressive disorder).
The UK Biobank recorded the 2-item Patient Health Questionnaire 2 (PHQ-2; range, 0-6;
3 indicates possible depressive disorder).
MAIN OUTCOMES AND MEASURES Primary outcomes were incident fatal or nonfatal coronary
heart disease (CHD), stroke, and CVD (composite of the 2). Hazard ratios (HRs) per 1-SD
higher log CES-D or PHQ-2 adjusted for age, sex, smoking, and diabetes were reported.
RESULTS Among 162 036 participants from the ERFC (73%, women; mean age at baseline, 63
years [SD, 9 years]), 5078 CHD and 3932 stroke events were recorded (median follow-up,
9.5 years). Associations with CHD, stroke, and CVD were log linear. The HR per 1-SD higher
depression score for CHD was 1.07 (95% CI, 1.03-1.11); stroke, 1.05 (95% CI, 1.01-1.10); and
CVD, 1.06 (95% CI, 1.04-1.08). The corresponding incidence rates per 10 000 person-years of
follow-up in the highest vs the lowest quintile of (CES-D) score (geometric mean CES-D score,
19 vs 1) were 36.3 vs 29.0 for CHD events, 28.0 vs 24.7 for stroke events, and 62.8 vs 53.5 for
CVD events. Among 401 219 participants from the UK Biobank (55% were women, mean age
at baseline, 56 years [SD, 8 years]), 4607 CHD and 3253 stroke events were recorded
(median follow-up, 8.1 years). The HR per 1-SD higher depression score for CHD was 1.11 (95%
CI, 1.08-1.14); stroke, 1.10 (95% CI, 1.06-1.14); and CVD, 1.10 (95% CI, 1.08-1.13). The
corresponding incidence rates per 10 000 person-years of follow-up among individuals with
PHQ-2 scores of 4 or higher vs 0 were 20.9 vs 14.2 for CHD events, 15.3 vs 10.2 for stroke
events, and for 36.2 vs 24.5 for CVD events. The magnitude and statistical significance of the
HRs were not materially changed after adjustment for additional risk factors.
CONCLUSIONS AND RELEVANCE In a pooled analysis of 563 255 participants in 22 cohorts,
baseline depressive symptoms were associated with CVD incidence, including at symptom
levels lower than the threshold indicative of a depressive disorder. However, the magnitude
of associations was modest.
JAMA. 2020;324(23):2396-2405. doi:10.1001/jama.2020.23068





affiliations are listed at the end of this
article.
Corresponding Author: Lisa
Pennells, PhD, BHF Cardiovascular
Epidemiology Unit, Department of
Public Health and Primary Care,
University of Cambridge,
Strangeways Research Laboratory,
Cambridge CB1 8RN, UK (lamp2@
medschl.cam.ac.uk).
Research
JAMA | Original Investigation
2396 (Reprinted) jama.com
© 2020 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a Cambridge University Library User  on 01/12/2021
D epressive disorders are a leading and growing cause ofdisability, with more than an estimated 264 millionpeople affected worldwide.1 Previous studies have re-
ported on potential links between depressive disorders, symp-
toms of lower mood, and cardiovascular disease (CVD).2-13
Position papers of the American Heart Association and the
European Society of Cardiology have acknowledged that de-
pression may be a modifiable prognostic factor for coronary
heart disease (CHD), encouraging improvement of its recog-
nition and management.14,15
There are, however, uncertainties in the epidemiological
evidence underpinning this possible link. First, several stud-
ies have used broad psychological measures of distress, leav-
ing doubt about whether depressive symptoms per se are as-
sociated with CVD risk.10,13 Second, most studies have had
limited statistical power, preventing reliable characterization
of the relationships across the spectrum of severity of depres-
sive symptoms. Third, studies have used varying approaches
to adjust for potential confounding factors, preventing robust
inference about the independence of associations from estab-
lished CVD risk factors.3-7,9,11,12 Fourth, studies have used in-
consistent disease definitions, preventing standardized analy-
sis of CVD subtypes or direct comparisons of associations of
depressive symptoms across multiple conditions.2-7,10,12
To help address these uncertainties, the present study
pooled individual-participant data from multiple long-term
prospective studies to evaluate the relationship between de-
pressive symptoms and incident CVD.
Methods
Data Sources and Participant Inclusion
This study, which was approved by the Cambridgeshire Ethics
Review Committee, was designed and conducted by the
Emerging Risk Factors Collaboration (ERFC) academic coor-
dinating center. Informed consent was obtained from partici-
pants in each contributing cohort. Data were analyzed from 2
sources: first the ERFC, a consortium of prospective cohort
studies with information on a variety of cardiovascular risk fac-
tors; second, the UK Biobank, a single large prospective study.
Both data sets involved a prospective cohort study design and
have accessible individual-participant data, enabling stan-
dardized and detailed analyses using a common protocol.16,17
Nevertheless, we conducted parallel analyses of the 2 data
sources owing to potential differences in methods used to as-
sess depressive symptoms.
Participants were eligible for inclusion in the current analy-
sis if they met the following criteria: (1) had a documented as-
sessment of depressive symptoms recorded at baseline using
a validated or published questionnaire; (2) did not have a
known baseline history of CVD (defined as CHD, other heart
disease, stroke, transient ischemic attack, peripheral vascu-
lar disease, or cardiovascular surgery); and (3) had at least 1 year
of follow-up after baseline. Details of contributing studies are
presented in Figure 1, in eTables 1 and 2, and eAppendix 1 in
the Supplement. In the ERFC, baseline assessments were con-
ducted between 1974 and 2010, and the date of latest follow-up
was March 2020; in the UK Biobank, the baseline assessment
was conducted between 2006 and 2010, and the date of lat-
est follow-up used for this analysis was March 2020.
Assessment of Depressive Symptoms
Twenty-one studies from the ERFC had relevant data and
contributed to the present analysis. Seven used the Center for
Epidemiological Studies Depression (CES-D) scale,18 5 used a
modified or abbreviated version of the CES-D,19 3 used the
Cohort of Norway Mental Health Index,20 and 6 used the fol-
lowing study-specific questionnaires: the Beck Depression
Inventory, the Hospital Anxiety and Depression Scale
(depression-specific subscale), the Human Population Labo-
ratory Depression scale, a modified version of the Minnesota
Multiphasic Personality Inventory, a Mental Health Inventory
derived from the 36-item Short Form Health Survey, and the
Zung Self-Rating Depression Scale (eTable 3 and eAppendix 2
in the Supplement). Depression scores were harmonized
across the cohorts to reflect the CES-D scale (eAppendix 3 in
the Supplement), a 20-item scale designed to assess the fre-
quency of depressive symptoms for the previous week. Items
in the CES-D are evaluated on a 4-point scale from 0 (rarely)
to 3 (most or all of the time). Thus, the CES-D score can range
from 0 to 60. A score of 16 or higher is indicative of a possible
depressive disorder.18 To enhance validity of findings
obtained using the transformed scale, results were directly
compared between studies that used and did not originally
use the full CES-D scale. In the UK Biobank, the Patient
Health Questionnaire-2 (PHQ-2) was used to assess depres-
sive symptoms at baseline. This 2-item instrument asks
about the frequency of depressed mood and anhedonia over
the past 2 weeks, with response options being “not at all,”
“several days,” “more than half the days,” and “nearly every
day,” scored as 0, 1, 2, and 3, respectively. Thus, the PHQ-2
score can range from 0 to 6; a score 3 of more is indicative of
possible depressive disorder.21
Outcomes
The primary end points were fatal or nonfatal CHD (defined
as fatal CHD or nonfatal myocardial infarction), stroke, and their
Key Points
Question Are depressive symptoms associated with incident
cardiovascular diseases?
Findings In a pooled analysis of individual-participant data from
563 255 participants in 22 prospective cohorts, depressive
symptoms (assessed by the Center for Epidemiologic Studies
Depression [CES-D] scale and other validated scales) were
significantly associated with incident cardiovascular disease,
including scores lower than the threshold typically indicative of
depressive disorders (CES-D 16; hazard ratio per 1-SD higher log
CES-D, 1.06).
Meaning Depressive symptoms, even at levels lower than what is
typically indicative of potential clinical depression, were associated
with risk of incident cardiovascular disease although the
magnitude of the association was modest.
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composite end point CVD. Participants contributed follow-up
time to the first CVD outcome recorded (ie, CVD deaths pre-
ceded by nonfatal CVD outcomes were not included). Second-
ary end points were all-cause mortality, mortality due to CVD,
mortality due to cancer, and mortality not attributable to either
cancer or CVD. For the analysis of all-cause mortality, all deaths
were included with no censoring for nonfatal events.
Statistical Analysis
The CES-D score distribution was normalized using a natural
log transformation before analysis. Cross-sectional correlates
of depressive symptom scores were estimated using linear
mixed models adjusted for age, sex, and cohort-level random
effects and were presented by differences in depressive
symptom scores per 1-SD higher level for continuous corre-
lates or category for categorical correlates. To evaluate asso-
ciations of depressive symptoms with primary and secondary
outcomes, hazard ratios (HRs) were calculated separately
within each study using Cox proportional hazards regression
models with time on study as the timescale and stratified
by sex. Hazard ratios were pooled across studies contributing
to the ERFC using a random-effects meta-analysis.22,23
Violation of the proportional hazards assumption was tested
by including time interactions with depressive symptoms.
To avoid model overfitting, studies with fewer than 10 inci-
dent cases of an outcome were excluded from analysis of that
particular outcome.
To maximize the available data and to limit potential over-
adjustment for variables that could mediate associations be-
tween depressive symptoms and CVD, the basic models were
stratified by sex and adjusted for age, smoking, and history of
diabetes only (with only participants with complete data for
these covariates included in the models). To evaluate the in-
dependence of the associations, HRs were further adjusted for
systolic blood pressure, body mass index (BMI), total and high-
density lipoprotein cholesterol (HDL-C), C-reactive protein
(CRP), self-reported race (White; non-White), educational level
(no schooling or primary; secondary; university or voca-
tional), and alcohol consumption (current; former; never),
which were defined by each study.
To assess the relationship between depressive symptoms
and CVD, HRs for CVD outcomes within quintiles or catego-
ries of depressive symptom scores were plotted against the
mean value within each quintile or category.22 We estimated
95% CIs for each group (including the reference group) that cor-
responded to the amount of information underlying each
group.24 Deviance from log-linear associations was assessed
using fractional polynomials,25 and HRs were thereafter cal-
culated per 1-SD higher depressive symptom scores (for log
CES-D, this corresponds to a 2.7-fold increase in CES-D score).
To investigate reverse causality, HRs were calculated with pro-
gressive exclusion of events recorded during the initial years
of follow-up. Hazard ratios were also calculated using thresh-
olds for depressive symptom scores typically indicative of
a possible depressive disorder, ie, 16 or higher for the CES-D
and 3 or higher for the PHQ-2 scores.
To place findings in context, HRs for depressive symp-
toms were compared with those for several established CVD
risk factors. Effect modification was assessed using formal tests
for interaction between depressive symptom scales and vari-
ous individual- and study-level characteristics.22 In ERFC,
heterogeneity in HRs across studies was quantified using the
I2 statistic.26
Analyses were performed using Stata version 16.1
(StataCorp) with 2-sided P values. We used a significance level
of P < .05, unless otherwise specified. Given the potential for
type I error due to multiple comparisons, findings should be
interpreted as exploratory.
Results
Of the 162 036 participants (mean baseline age, 63 years [SD,
9 years]) from 21 studies in ERFC, 117 778 participants (73%)
were women. Most participants were enrolled in either North
America (67%) or Europe (26%). During a median follow-up
of 9.5 years (5th-95th percentile, 1.9-16.9 years), 9010 inci-
dent CVD events (5078 CHD and 3932 stroke) and 23 660
deaths (including 4807 CHD or stroke and 7289 cancer
deaths) were recorded. Of the 401 219 participants in the UK
Biobank (mean baseline age, 56 years [SD, 8 years]), 221 660
participants (55%) were women. During a median follow-up
of 8.1 years (5th-95th percentile, 6.7-9.4 years), 7860 incident
CVD events (4607 CHD and 3253 stoke) and 18 516 deaths
(2434 CVD, 11 440 cancer, and 4642 other causes) were
recorded (eTable 1 in the Supplement). Study-specific distri-
butions of baseline depressive symptom scores differed sub-
stantially across questionnaire types but were similar after
transformation to the harmonized CES-D scale in the ERFC
(eFigure 1 in the Supplement). Depressive symptom scales
were positively correlated with age, female sex, history of
diabetes, smoking status, measures of adiposity (ie, waist-hip
ratio and BMI), triglyceride levels, and CRP, whereas they
were inversely correlated with educational attainment and
HDL-C levels (all P < .01; eTable 2, eTable 4, and eFigures 2-3
in the Supplement).
After adjustment for age, sex, smoking status, and history
of diabetes, there were significant log-linear associations
Figure 1. Selection of Eligible Studies and Participants From
the Emerging Risk Factors Collaboration and the UK Biobank
Emerging Risk Factors Collaboration
157 Studies
1 912 604 Participants
UK Biobank
1 Study across 22 centers
502 506 Participants
162 036 Included in the analysis
from 21 studies
401 219 Included in the analysis
31 820 Excluded
8270 Missing age or sex
23 550 Lacked smoking status,
diabetes history, or
depression score
30 337 Excluded (lacked smoking
status, diabetes history, or
depression score)
193 856 Eligible participantswith no
prior cardiovascular disease
from 21 studies using a
validated depression scale 
431 556 Eligible participants with no
prior cardiovascular disease
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between depressive symptom scores and incidence of CHD,
stroke, or CVD (Figure 2 and eFigures 4-5 in the Supplement;
models fit with fractional polynomials revealed no evidence
for nonlinearity; all P values > .40). For the ERFC, the ad-
justed incidence rate per 10 000 person-years of follow-up in
the highest vs lowest quintile of CES-D scores (geometric mean
CES-D score, 19 vs 1) was 36.3 vs 29.0 for CHD events, 28.0 vs
24.7 for stroke events, and 62.8 vs 53.5 for CVD events (Figure 2
and eTable 5 in the Supplement). Adjusted HRs per 2.7-fold in-
crease in CES-D score (ie, 1 SD) were 1.07 (95% CI, 1.03-1.11) for
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HR, 1.10 (95% CI, 1.08-1.13)
Emerging Risk Factors Collaboration UK Biobank
Hazard ratio (HR) reported is per 1-SD increase in depressive symptoms,
adjusted for age, sex (stratified), smoking status, and history of diabetes. Values
on the x-axis display the geometric mean Center for Epidemiological Studies
Depression (CES-D) scale within quintiles across all studies (plotted on a log
scale), or the 2-item Patient Health Questionnaire (PHQ-2) depression score.
Floating absolute variances were used to derive 95% CIs (indicated by error
bars) from the variances that corresponded to the amount of information
underlying each group (including the reference group).
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CHD, 1.05 (95% CI, 1.01-1.10) for stroke, and 1.06 (95% CI, 95%
CI, 1.04-1.08) for CVD (Figure 3 and Table). Likewise, for UK
Biobank participants with PHQ-2 scores of 4 or higher vs 0, the
incidence rate per 10 000 person-years was 20.9 vs 14.2 for CHD
events, 15.3 vs 10.2 for stroke events, and 36.2 vs 24.5 for CVD
events (Figure 2 and eTable 5 in the Supplement). Adjusted HRs
per 1-unit increase in PHQ-2 score (ie, 1 SD) were 1.11 (95% CI,
1.08-1.14) for CHD, 1.10 (95% CI, 1.06-1.14) for stroke, and 1.10
(95% CI, 1.08-1.13) for CVD (Figure 3 and Table).
In comparison, among ERFC participants, the HR per 1-SD
higher systolic blood pressure was 1.31 (95% CI, 1.28-1.34); non–
HDL-C, 1.18 (95% CI, 1.14-1.22); and BMI, 1.17 (95% CI, 1.11-
1.24), reflecting event rates per 10 000 person-years in the high-
est vs lowest quintile of 55.6 vs 24.2 for systolic blood pressure,
44.8 vs 31.2 for non–HDL-C, and 61.0 vs 43.5 for BMI. For the
UK Biobank, these HRs were 1.32 (95% CI, 1.29-1.35) per 1-SD
higher systolic blood pressure, 1.27 (95% CI, 1.24-1.30) for non–
HDL-C, and 1.16 (95% CI, 1.13-1.18) for BMI, reflecting event rates
per 10 000 person-years in the highest vs the lowest quintile
of 23.7 vs 10.7 for systolic blood pressure, 39.6 vs 21.2 for non–
HDL-C, and 24.5 vs 16.5 for BMI (Figure 4; eTable 5 in the
Supplement).
The HRs did not vary in magnitude or statistical signifi-
cance after further analyses, including additional adjustment
for systolic blood pressure, BMI, total cholesterol, HDL-C, race,
educational attainment, alcohol consumption, or CRP (Table;
eTable 6 in the Supplement); after exploration for effect modi-
fication by baseline smoking status, sex, history of diabetes,
use of antidepressant medications (or medical care related to
depressive symptoms), symptom questionnaire, or geographi-
cal region (eFigures 6 and 7 in the Supplement); and after ex-
clusion of events occurring during the initial years of follow-up
(eTable 7 in the Supplement). Hazard ratios for CHD were
smaller in magnitude at older ages in the ERFC (P value for in-
teraction = .003, eFigure 6 in the Supplement). Further-
more, HRs did not vary in magnitude or statistical signifi-
cance in sensitivity analyses that (1) used only studies that
recorded depressive symptoms using a CES-D questionnaire;
(2) used inverse normal rank-transformed depression scores
rather than the harmonized CES-D scale; (3) excluded the larg-
est study in the ERFC; and (4) excluded participants with a his-
tory of diabetes or other non-CVD comorbidities, such as rheu-
matoid arthritis or inflammatory bowel disease, at baseline
(eFigures 8 through 13 in the Supplement). The extent of
heterogeneity in HRs across studies contributing to the ERFC
was moderate, with I2 values of 15% (95% CI, 0%-49%) for CHD,
1% (95% CI, 0%-47%) for stroke, and 12% (95% CI, 0%,-48%)
for CVD outcomes (eFigure 8 in the Supplement).
In a comparison of a depressive symptom score higher or
lower than the threshold indicative of potential depressive
Figure 3. Adjusted Hazard Ratios for Cause-Specific Mortality and Major Cardiovascular Disease
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person-yearsEnd point or condition
Vascular morbidity and mortalityb
HR (95% CI)
Emerging Risk Factors Collaboration results (CES-D)A
9010 1 629 450CVD 1.06 (1.04-1.08)
5078 1 629 450CHD 1.07 (1.03-1.11)
3922 1 600 603Stroke 1.05 (1.01-1.10)
Mortality
23 660 1 810 569All-cause mortality 1.09 (1.07-1.11)
4800 1 808 619CVD mortality 1.09 (1.06-1.12)
7280 1 690 271Cancer mortality 1.05 (1.00-1.09)






Adjusted HR (95% CI) per 1-SD




person-yearsEnd point or condition
Vascular morbidity and mortalityb
HR (95% CI)
UK Biobank results (PHQ-2)B
7860 3 188 760CVD 1.10 (1.08-1.13)
4607 3 188 760CHD 1.11 (1.08-1.14)
3253 3 188 760Stroke 1.10 (1.06-1.14)
Mortality
19 555 4 394 342All-cause mortality 1.15 (1.13-1.16)
2434 4 394 342CVD mortality 1.18 (1.14-1.22)
11 440 4 394 342Cancer mortality 1.07 (1.05-1.09)
4642 4 394 342Noncancer non-CVD mortality 1.31 (1.27-1.34)
a Adjusted for age, sex (stratified),
smoking status, and history of
diabetes. Studies with fewer than 10
events were excluded from the
analysis of each outcome. A 1-SD
increase in depression score
corresponds to a 2.7-fold increase in
the CES-D and 1-unit increase in the
PHQ-2 scores.
b Includes fatal and nonfatal events.
CES-D indicates, Center for
Epidemiological Studies Depression
scale; CHD, coronary heart disease;
CVD, cardiovascular disease;
HR, hazard ratio; and PHQ-2, 2-item
Patient Health Questionnaire.
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disorder (ie, CES-D ≥ 16 vs <16, and PHQ-2 ≥ 3 vs <3), HRs were
1.16 (95% CI, 1.00-1.35) for CHD, 1.07 (95% CI, 0.97-1.18) for
stroke, and 1.10 (95% CI, 1.01-1.21) for CVD in ERFC. For the UK
Biobank, the HRs were 1.34 (95% CI, 1.20-1.51) for CHD, 1.42
(95% CI, 1.24-1.63) for stroke, and 1.38 (95% CI, 1.26-1.50) for
CVD (eFigures 14-15 in the Supplement).
When considering only individuals with depressive symp-
toms lower than the threshold indicative of depressive disor-
der HRs per 1-SD higher depressive symptoms score, CES-D
were 1.07 (95% CI, 1.02-1.12) for CHD, 1.06 (95% CI, 1.00-1.12)
for stroke, and 1.06 (95% CI, 1.03-1.09) for CVD in ERFC. For
the UK Biobank, the HRs per 1-SD increase in PHQ-2 score were
1.12 (95% CI, 1.07-1.17) for CHD, 1.07 (95% CI, 1.02-1.13) for
stroke, and 1.10 (95% CI, 1.06-1.14) for CVD (eFigure 16 in the
Supplement). In an exploratory comparison in the UK Biobank
of any episode of major depression reported over the life course
vs none,27 the HRs were 1.27 (95% CI, 1.09-1.47) for CHD, 0.99
(95% CI, 0.82-1.20) for stroke, and 1.15 (95% CI, 1.02-1.29) for
CVD (eFigure 17 in the Supplement).
In analyses of secondary outcomes of the ERFC, HRs per
1-SD higher depressive symptom scores were 1.08 (95% CI, 1.05-
1.11) for CVD mortality, 1.05 (95% CI, 1.00-1.09) for cancer mor-
tality, and 1.17 (95% CI, 1.12-1.23) for noncancer or non-CVD
mortality. The HRs in the UK Biobank were 1.17 (95% CI, 1.13-
1.16) for CVD mortality, 1.07 (95% CI, 1.05-1.09) for cancer mor-
tality, and 1.31 (95% CI, 1.27-1.34) for noncancer or non-CVD
mortality (Figure 3). For the last category, HRs were highest
for nervous system disorders (eg, Alzheimer disease), but data
were sparse in this exploratory subanalysis (eFigures 18-19 in
the Supplement). There was no evidence of publication bias
or small studies effect in the current results (eFigure 20 in the
Supplement).
Discussion
In an analysis of 563 255 participants in 22 prospective stud-
ies, baseline depressive symptoms were associated with CVD
Table. Hazard Ratios per 1-SD Higher Depressive Symptoms Scores on Progressive Adjustment for Cardiovascular Disease Risk Markers
Emerging Risk Factors Collaboration results UK Biobank results
HR (95% CI) per 1-SD higher log CES-Da HR (95% CI) per 1-SD higher PHQ-2b
CHD Stroke CVD CHD Stroke CVD
Basic adjustment
No. of cohorts 21 19 21 1 1 1
Events 5078 3922 9010 4607 3253 7860
Person-years 1 629 450 1 600 603 1 629 450 3 188 760 3 188 760 3 188 760
Adjusted for age and sex 1.09 (1.05-1.14) 1.07 (1.02-1.12) 1.08 (1.05-1.11) 1.15 (1.12-1.18) 1.13 (1.10-1.17) 1.14 (1.12-1.17)
+Smoking status 1.08 (1.04-1.12) 1.06 (1.01-1.11) 1.07 (1.05-1.09) 1.11 (1.08-1.14) 1.11 (1.07-1.15) 1.11 (1.09-1.13)
+History of diabetes 1.07 (1.03-1.11) 1.05 (1.01-1.10) 1.06 (1.04-1.08) 1.11 (1.08-1.14) 1.10 (1.06-1.14) 1.10 (1.08-1.13)
Further adjustment
No. of cohorts 9 9 10 1 1 1
Events 1390 897 2299 3903 2732 6635
Person-years 505 438 492 893 513 741 2 700 169 2 700 169 2 700 169
Basic adjustmentc 1.10 (1.03-1.18) 1.12 (1.04-1.20) 1.10 (1.05-1.15) 1.10 (1.06-1.13) 1.10 (1.06-1.14) 1.10 (1.07-1.12)
+Systolic blood pressure 1.10 (1.03-1.18) 1.12 (1.04-1.20) 1.10 (1.05-1.15) 1.11 (1.07-1.14) 1.11 (1.07-1.15) 1.11 (1.08-1.13)
+Body mass index 1.09 (1.02-1.18) 1.11 (1.03-1.19) 1.09 (1.05-1.15) 1.10 (1.07-1.13) 1.10 (1.06-1.14) 1.10 (1.08-1.13)
+Total cholesterol 1.10 (1.02-1.18) 1.11 (1.03-1.19) 1.10 (1.05-1.15) 1.10 (1.06-1.13) 1.10 (1.06-1.15) 1.10 (1.07-1.13)
+HDL cholesterol 1.10 (1.02-1.18) 1.11 (1.03-1.19) 1.10 (1.05-1.15) 1.09 (1.06-1.13) 1.10 (1.06-1.14) 1.10 (1.07-1.12)
+Educational leveld 1.09 (1.02-1.17) 1.11 (1.03-1.19) 1.09 (1.04-1.14) 1.09 (1.06-1.12) 1.10 (1.06-1.14) 1.09 (1.07-1.12)
+Alcohol consumption
status
1.09 (1.02-1.17) 1.11 (1.03-1.19) 1.09 (1.04-1.14) 1.08 (1.05-1.12) 1.09 (1.05-1.13) 1.09 (1.06-1.11)
Basic adjustment plus markers
of inflammation
No. of cohorts 5 5 6 1 1 1
Events 876 585 1472 4301 3031 7332
Person-years 158 448 162 382 169 509 2 975 605 2 975 605 2 975 605
Basic adjustmentc 1.05 (0.98-1.13) 1.06 (0.93-1.21) 1.07 (1.01-1.13) 1.10 (1.06-1.13) 1.09 (1.06-1.13) 1.10 (1.08-1.13)
+Log C-reactive protein 1.04 (0.96-1.12) 1.06 (0.93-1.20) 1.06 (1.00-1.12) 1.08 (1.05-1.12) 1.08 (1.04-1.12) 1.09 (1.07-1.11)
Abbreviations: CES-D, Center for Epidemiological Studies Depression (CES-D)
scale; CHD, coronary heart disease; CVD, cardiovascular disease;
HDL, high-density lipoprotein; PHQ-2, 2-item Patient Health
Questionnaire.
a A 1-SD higher log CES-D depression score corresponds to a 2.7-fold higher
CES-D depression score (range, 0-60; scores 16 indicate possible
depressive disorder).
b 1-SD higher PHQ-2 depression score corresponds to a 1-unit higher PHQ-2
depression score (range, 0-6, 3 indicates possible depressive disorder).
c The basic adjustment consists of adjustment for age, sex (stratified), smoking
status, and history of diabetes.
d Educational level is categorized as no schooling or primary, secondary,
or vocational or university.
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incidence, including at symptom levels lower than the thresh-
old indicative of a potential depressive disorder. Associations
persisted after adjustment for several cardiovascular risk fac-
tors and after attempts to limit the effects of reverse causal-
ity. The current data are consistent with the existence of as-
sociations between depressive symptoms across the spectrum
of low mood and subsequent risk of major CVD outcomes.
This study extends previous work on this topic in several
ways. First, the current data indicate that there are log-linear
associations of depressive symptoms with CVD incidence,
suggesting no clear evidence for a threshold level below
which depressive symptoms are not associated with CVD
risk. This observation supports the concept that prevention of
CVD via addressing depressive symptoms could, in principle,
Figure 4. Adjusted Hazard Ratios for Coronary Heart Disease, Stroke, and Cardiovascular Disease per 1-SD Higher Depressive Symptoms






Adjusted HR (95% CI)











Emerging Risk Factors Collaboration results (CES-D)A
4820158 23418 1 586 396 13.9 28.0Systolic blood pressure 1.29 (1.24-1.33)
1629 15.9 28.364 11513 563 922Non-HDL cholesterol 1.24 (1.19-1.29)
4434 22.5 37.0151 38815 1 510 055Body mass index 1.20 (1.14-1.26)
5078 29.0 36.3162 03621 1 629 450Depression score 1.07 (1.03-1.11)
Stroke
3666150 48716 1 558 980 10.4 28.0Systolic blood pressure 1.34 (1.29-1.39)
1099 15.5 15.756 61811 537 929Non-HDL cholesterol 1.03 (0.95-1.12)
3386 21.2 24.3143 67413 1 482 630Body mass index 1.11 (1.02-1.20)
3922 24.7 28.0154 09919 1 600 603Depression score 1.05 (1.01-1.10)
CVD
8496158 23418 1 586 396 24.2 55.6Systolic blood pressure 1.31 (1.28-1.34)
2737 31.2 44.864 11513 563 922Non-HDL cholesterol 1.18 (1.14-1.22)
7830 43.5 61.0151 38815 1 510 055Body mass index 1.17 (1.11-1.24)
9010 53.5 62.8162 03621 1 629 450Depression score 1.06 (1.04-1.08)
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UK Biobank results (PHQ-2)B
4599400 5341 3 183 350 5.9 13.5Systolic blood pressure 1.32 (1.29-1.36)
3961 10.6 28.2343 6731 2 726 557Non-HDL cholesterol 1.45 (1.41-1.49)
4580 8.2 14.3399 4291 3 175 283Body mass index 1.19 (1.15-1.22)
4607 14.2 20.9401 2191 3 188 760Depression score 1.11 (1.08-1.14)
Stroke
3243400 5341 3 183 350 4.8 10.1Systolic blood pressure 1.30 (1.26-1.35)
2782 10.6 11.8343 6731 2 726 557Non-HDL cholesterol 1.03 (0.99-1.07)
3223 8.3 10.1399 4291 3 175 283Body mass index 1.11 (1.07-1.15)
3253 10.2 15.3401 2191 3,188,760Depression score 1.10 (1.06-1.14)
CVD
7842400 5341 3 183 350 10.7 23.7Systolic blood pressure 1.32 (1.29-1.35)
6743 21.2 39.6343 6731 2 726 557Non-HDL cholesterol 1.27 (1.24-1.30)
7803 16.5 24.5399 4291 3 175 283Body mass index 1.16 (1.13-1.18)
7860 24.5 36.2401 2191 3 188 760Depression score 1.10 (1.08-1.13)






Hazard ratios (HRs) for continuous variables are per 1-SD higher baseline values.
Risk factors were adjusted for age, sex, smoking status, history of diabetes,
and depression score.
CES-D indicates Center for Epidemiological Studies Depression scale;
CHD, coronary heart disease; CVD, cardiovascular disease; HDL, high-density
lipoprotein; PHQ-2, 2-item Patient Health Questionnaire.
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be amenable to population-wide, rather than targeted, ap-
proaches. At present, however, it is uncertain whether treat-
ment of depression can reduce CVD risk.15 Second, the cur-
rent findings suggest that associations between depressive
symptoms and CVD risk cannot be chiefly explained by sev-
eral established or emerging cardiovascular risk factors, in-
cluding systolic blood pressure, total cholesterol, HDL-C, BMI,
diabetes, alcohol consumption, or CRP. Previous studies have
proposed mechanisms including altered brain and neuronal
function affecting neuroendocrine pathways, autonomic nerve
dysfunction, immune responses, platelet activation and throm-
bosis, life behavior, and cardiac metabolic risk factors.2,15
Third, associations of depressive symptoms with CVD were
considerably smaller in magnitude than those for systolic blood
pressure, non–HDL-C, and BMI. An implication is that there
is the need for studies of depressive symptoms and CVD to en-
sure adequate statistical power to enable reliable evaluation.
Nevertheless, the population attributable risk of CVD due to
lower mood could still be substantial because depressive symp-
toms are common. Further studies are needed, however, to de-
termine whether there is a cause-and-effect relationship be-
tween depressive symptoms and CVD.28 Fourth, this study
showed that depressive symptoms were associated with a wide
range of causes of death, including cancer and non-CVD or non-
cancer mortality. These findings reinforce previous observa-
tions, highlighting the potential need to investigate the pres-
ence of depression and depressive symptoms including among
people who would not usually come to the attention of men-
tal health services, and to monitor those expressing symp-
toms with increased vigilance.
This study had several strengths, including substantial sta-
tistical power, based on 16 870 incident CVD outcomes; focus
on prospective cohort data; and use of information from 2 well-
characterized studies that provided complementary sources
of cohort data with respect to geographical region and calen-
dar period of recruitment. The limitations of literature-based
meta-analyses were avoided by accessing individual-
participant data from cohorts, enabling detailed and standard-
ized analyses. To limit potential effects of a CVD diagnosis on
depressive symptoms (ie, reverse causality), analyses were re-
stricted to individuals without a history of CVD at baseline and
the initial years of follow-up were excluded. The generaliz-
ability of the findings, at least to populations in Western coun-
tries, was supported by broadly consistent results observed
from 22 cohorts in 8 different countries, mainly in North
America and Europe. The focus on populations in Western
countries reduced the scope for bias due to different cultur-
ally determined mental health perceptions. Findings were
broadly concordant across multiple subgroups and across dif-
ferent depressive symptom scales used.
Limitations
This study had several limitations. First, it was not a system-
atic review: for pragmatic reasons, this study focused on the UK
Biobank and 21 cohorts contributing to the ERFC with readily
available individual-participant data. These findings do not,
therefore, constitute a comprehensive synthesis of the avail-
able evidence. The results should, however, be based on a sub-
stantial and unbiased subset of relevant studies because co-
horts in the ERFC were collated about a decade ago principally
on the basis of availability of biochemical risk-factor data and
not on the basis of depressive symptoms. Moreover, there was
no evidence of publication bias in the current results. Second,
contributing cohorts used a variety of depressive symptom ques-
tionnaires, potentially yielding inconsistencies. However, data
across these scales were harmonized and, furthermore, were
consistent across different questionnaires used.
Third, this analysis focused on depressive symptoms as-
sessed at a single baseline examination, preventing investiga-
tion of cumulative depression burden, of incident depres-
sion, or of time-varying associations with outcomes. Such
misclassification could have underestimated true associa-
tions, or even produced artifactual log-linear relationships.
However, according to previous studies, depressive symp-
toms assessed by the CES-D are reasonably stable over
adulthood,29,30 and, moreover, in an analysis involving frac-
tional polynomials, which should avoid selection of artificial
cut points for continuous variables, the evidence for log-
linear relationships persisted.25
Fourth, this study cannot exclude inadequate adjust-
ment for unmeasured or imprecisely measured confounding
factors, including various baseline comorbidities. Fifth, these
analyses included only participants with complete informa-
tion on risk factors, which could in principle have reduced ef-
ficiency and biased results. However, these analyses were well-
powered and should be unbiased under the reasonable
assumption that the probability of being a complete case was
independent of CVD outcomes, given the variables included
in the models. Sixth, the present analysis involved partici-
pants who were mostly of European continental ancestry, sug-
gesting the need for well-powered studies in other ethnic and
racial groups.
Conclusions
In a pooled analysis of 563 255 participants in 22 prospective
studies, baseline depressive symptoms were associated
with CVD incidence, including at symptom levels lower than
the threshold indicative of a depressive disorder. However, the
magnitude of associations was modest.
ARTICLE INFORMATION
Accepted for Publication: November 4, 2020.
Correction: This article was corrected December
21, 2020, to remove the word log from the x-axis in
panel B of Figure 3.
Author Affiliations: Department of Public Health
and Primary Care, University of Cambridge,
Cambridge, United Kingdom (Harshfield, Pennells,
Willeit, Kaptoge, Bell, Bolton, Spackman, Wood,
Danesh, Di Angelantonio); Department of Clinical
Neurosciences, University of Cambridge,
Cambridge, United Kingdom (Harshfield, Bell);
Center for Behavioral Cardiovascular Health,
Columbia University Medical Center, New York,
New York (Schwartz); Applied Behavioral Medicine
Research Institute, Stony Brook University, Stony
Brook, New York (Schwartz); Department of
Neurology & Neurosurgery, Medical University of
Innsbruck, Innsbruck, Austria (Willeit); University of
Colorado Denver, Denver (Shaffer); Department of
Epidemiology and Population Health, Albert
Einstein College of Medicine, Bronx, New York
(Wassertheil-Smoller); Centre for Public Health,
Association Between Depressive Symptoms and Incident Cardiovascular Diseases Original Investigation Research
jama.com (Reprinted) JAMA December 15, 2020 Volume 324, Number 23 2403
© 2020 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a Cambridge University Library User  on 01/12/2021
Queens University, Belfast, United Kingdom (Kee);
Institut Pasteur de Lille, Lille, France (Amouyel);
Columbia Field Center, Columbia University,
New York, New York (Shea); Department of
Epidemiology, University of Pittsburgh Graduate
School of Public Health, Pittsburgh, Pennsylvania
(Kuller); Institute of Public Health and Clinical
Nutrition, University of Eastern Finland, Kuopio,
Finland (Kauhanen); Department of Psychiatry,
Amsterdam Public Health Research Institute,
Amsterdam UMC at VU University Medical Center,
Amsterdam, the Netherlands (van Zutphen);
Department of Epidemiology and Biostatistics,
Amsterdam Public Health Research Institute,
Amsterdam UMC at VU University Medical Center,
Amsterdam, the Netherlands (van Zutphen); GGZ
inGeest Specialized Mental Health Care,
Amsterdam, the Netherlands (van Zutphen);
Department of Psychiatry and Behavioral Sciences,
Duke University, Durham, North Carolina (Blazer);
Yale School of Medicine, New Haven, Connecticut
(Krumholz); Department of Public Health Sciences,
Medical University of South Carolina (Nietert);
Department of Epidemiology, University Medical
Centre Groningen, University of Groningen,
Groningen, the Netherlands (Kromhout); Family
Medicine & Public Health, University of California,
San Diego (Laughlin); Harvard T.H. Chan School of
Public Health, Boston, Massachusetts (Berkman);
Department of Epidemiology, University of Iowa
College of Public Health (Wallace); Faculty of
Medicine, UNSW, Sydney, Australia (Simons); MRC
Lifecourse Epidemiology Unit, University of
Southampton, Southampton, United Kingdom
(Dennison); Baker Heart and Diabetes Institute,
Melbourne, Australia (Barr); Norwegian Institute of
Public Health, Oslo, Norway (Meyer); Feinstein
Institutes for Medical Research, Northwell Health,
Manhasset, New York (Davidson).
Author Contributions: Dr Pennells and
Dr Di Angelantonio had full access to all of the data
in the study and take responsibility for the integrity
of the data and the accuracy of the data analysis.
Drs Harshfield, Pennells, and Schwartz contributed
equally.
Concept and design: Harshfield, Pennells, Willeit,
Bolton, Shea, Wood, Danesh, Di Angelantonio,
Davidson.
Acquisition, analysis, or interpretation of data: All
authors.
Drafting of the manuscript: Harshfield, Pennells,
Schwartz, Bolton, Shea, Nietert, Berkman, Wallace,
Danesh, Di Angelantonio, Davidson.
Critical revision of the manuscript for important
intellectual content: All authors.
Statistical analysis: Harshfield, Pennells, Schwartz,
Willeit, Kaptoge, Bolton, Amouyel, Shea, Simons,
Wood, Danesh, Di Angelantonio, Davidson.
Obtained funding: Schwartz, Wassertheil-Smoller,
Kee, Shea, Blazer, Kromhout, Berkman, Wallace,
Danesh, Di Angelantonio.
Administrative, technical, or material support:
Pennells, Bell, Bolton, Wassertheil-Smoller, Shea,
Kauhanen, Barr, Danesh, Di Angelantonio.
Supervision: Pennells, Willeit, Kaptoge, Shea,
Kromhout, Wallace, Danesh, Davidson.
Other-critical revision: Kee.
Conflict of Interest Disclosures: Dr Pennells
reported receiving grants from British Heart
Foundation (BHF). Dr Schwartz reported receiving
grants from the National Heart, Lung, and Blood
Institute (NHLBI). Dr Kaptoge reported receiving
grants from the BHF and the Medical Research
Council. Dr Bell reported receiving grants from the
National Institute for Health Research (NIHR) Blood
and Transplant Research Unit in Donor Health and
Genomics, the BHF, and the UK Medical Research
Council. Ms Spackman reported receiving grants
from BHF. Dr Wassertheil-Smoller reported
receiving grants from the National Institutes of
Health (NIH). Dr Kee reported receiving grants from
the UK Clinical Research Collaborative. Dr Amouyel
reported being the director of the Fondation
Alzheimer, a nonprofit organization, and receiving
personal fees from Genoscreen. Dr Shea reported
receiving grants from the NHLBI. Dr Krumholz
reported receiving personal fees from
UnitedHealth, IBM Watson Health, Element
Science, Aetna, Facebook, Siegfried & Jensen law
firm, Arnold & Porter law firm, Martin/Baughman
law firm, National Center for Cardiovascular
Diseases, Beijing; support from HugoHealth,
Refactor Health, Centers for Medicare & Medicaid
Services; and grants from Medtronic and the US
Food and Drug Administration, Medtronic and
Johnson & Johnson, and Shenzhen Center for
Health Information. Dr Nietert reported receiving
grants from the NIH. Dr Davidson reported
receiving grants from the NIH. No other disclosures
were reported.
Funding/Support: This research has been
conducted using the UK Biobank under application
number 63871. Drs Pennells and Kaptoge and
Ms Spackman are funded by grant RG/18/13/33946
from the British Heart Foundation Programme.
Dr Bell was funded by grant NIHR
BTRU-2014-10024 from the NIH for the Health
Research Blood and Transplant Research Unit in
Donor Health and Genomics. Mr Bolton is funded
by grant NIHR BTRU-2014-10024 from the NIH
Health Research Blood and Transplant Research
Unit in Donor Health and Genomics. Dr Wood is
supported by a BHF-Turing Cardiovascular Data
Science Award and by the EC-Innovative Medicines
Initiative (bigdata@heart). Dr Danesh holds a BHF
professorship and a NIHR senior investigator award.
The ERFC coordinating center was underpinned by
program grants SP/09/002; RG/13/13/30194 and
RG/18/13/33946 from the BHF and MR/L003120/1
from the UK Medical Research Council and the
NIHR (Cambridge Biomedical Research Centre at
the Cambridge University Hospitals NHS
Foundation Trust), with project-specific support
received from the UK NIHR. A variety of funding
sources have supported recruitment, follow-up,
and laboratory measurements in the studies
contributing data to the ERFC, which are listed on
the ERFC website (www.phpc.cam.ac.uk/ceu/erfc/
list-of-studies). This work was also supported by
Health Data Research UK, which is funded by the
UK Medical Research Council, Engineering and
Physical Sciences Research Council, Economic and
Social Research Council, Department of Health and
Social Care (England), Chief Scientist Office of the
Scottish Government Health and Social Care
Directorates, Health and Social Care Research and
Development Division (Welsh Government), Public
Health Agency (Northern Ireland), BHF, and
Wellcome.
Role of the Funder/Sponsor: The sponsors had no
role in the design and conduct of the study;
collection, management, analysis, and
interpretation of the data; preparation, review, or
approval of the manuscript; and decision to submit
the manuscript for publication.
Investigators of the Emerging Risk Factors
Collaboration: Australian Diabetes, Obesity and
Lifestyle Study: Jonathan E. Shaw, Robert Atkins,
Paul Z. Zimmet, and Dianna Magliano; Charleston
Heart Study: Susan E. Sutherland and Paul J.
Nietert; Dubbo Study of the Elderly: Judith Simons;
Established Populations for the Epidemiologic Study
of the Elderly East Boston, Established Populations
for the Epidemiologic Study of the Elderly Iowa City,
Established Populations for the Epidemiologic Study
of the Elderly North Carolina, Established
Populations for the Epidemiologic Study of the
Elderly New Haven: Jack Guralnik; Hertfordshire
Cohort Study: Cyrus Cooper; Oslo Health Study,
Oppland and Hedmark Health Study, Troms and
Finnmark Health Study: Haakon E. Meyer; Kuopio
Ischaemic Heart Disease Risk Factor Study: Jukka T.
Salonen, Tomi-Pekka Tuomainen, and Jyrki
Virtanen; Longitudinal Aging Study Amsterdam
(LASA): Almar Kok, Martijn Huisman, and Natasja
van Schoor; Multi-Ethnic Study of Atherosclerosis:
Moyses Szklo; Multiple Risk Factor Intervention Trial
1: Lewis H. Kuller; National Health and Nutrition
Examination Survey I: Hee-Choon Shin and Juan R.
Albertorio-Díaz; Nova Scotia Health Survey: Karina
Davidson; Jonathan A. Shaffer, Paul Muntner, and
Susan Kirkland; Prospective Epidemiological Study
of Myocardial Infarction: Frank Kee, Philippe
Amouyel, Jean Ferrières, and Marie Moitry; Rancho
Bernardo Study: Linda McEvoy; Women’s Health
Initiative Observational Study: Sylvia
Wassertheil-Smoller; and Zutphen Elderly Study:
Daan Kromhout and Erik J Giltay.
Disclaimer: The views expressed herein are those
of the authors and not necessarily those of the
NHS, the NIHR, or the Department of Health and
Social Care.
Additional Contributions: We thank investigators
and participants of the several studies who
contributed data to the Emerging Risk Factors
Collaboration (ERFC).
REFERENCES
1. GBD 2017 Disease and Injury Incidence and
Prevalence Collaborators. Global, regional, and
national incidence, prevalence, and years lived with
disability for 354 diseases and injuries for 195
countries and territories, 1990-2017: a systematic
analysis for the Global Burden of Disease Study
2017. Lancet. 2018;392(10159):1789-1858. doi:10.
1016/S0140-6736(18)32279-7
2. Carney RM, Freedland KE. Depression and
coronary heart disease. Nat Rev Cardiol. 2017;14(3):
145-155. doi:10.1038/nrcardio.2016.181
3. Wu Q, Kling JM. Depression and the risk of
myocardial infarction and coronary death:
a meta-analysis of prospective cohort studies.
Medicine (Baltimore). 2016;95(6):e2815. doi:10.
1097/MD.0000000000002815
4. Pan A, Sun Q, Okereke OI, Rexrode KM, Hu FB.
Depression and risk of stroke morbidity and
mortality: a meta-analysis and systematic review.
JAMA. 2011;306(11):1241-1249. doi:10.1001/jama.2011.
1282
5. Nicholson A, Kuper H, Hemingway H.
Depression as an aetiologic and prognostic factor in
coronary heart disease: a meta-analysis of 6362
events among 146 538 participants in 54
observational studies. Eur Heart J. 2006;27(23):
2763-2774. doi:10.1093/eurheartj/ehl338
Research Original Investigation Association Between Depressive Symptoms and Incident Cardiovascular Diseases
2404 JAMA December 15, 2020 Volume 324, Number 23 (Reprinted) jama.com
© 2020 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a Cambridge University Library User  on 01/12/2021
6. Li M, Zhang XW, Hou WS, Tang ZY. Impact of
depression on incident stroke: a meta-analysis. Int J
Cardiol. 2015;180:103-110. doi:10.1016/j.ijcard.
2014.11.198
7. Dong JY, Zhang YH, Tong J, Qin LQ. Depression
and risk of stroke: a meta-analysis of prospective
studies. Stroke. 2012;43(1):32-37. doi:10.1161/
STROKEAHA.111.630871
8. Wassertheil-Smoller S, Shumaker S, Ockene J,
et al; The Women’s Health Initiative (WHI).
Depression and cardiovascular sequelae in
postmenopausal women. Arch Intern Med. 2004;
164(3):289-298. doi:10.1001/archinte.164.3.289
9. Barlinn K, Kepplinger J, Puetz V, Illigens BM,
Bodechtel U, Siepmann T. Exploring the risk-factor
association between depression and incident
stroke: a systematic review and meta-analysis.
Neuropsychiatr Dis Treat. 2014;11:1-14. doi:10.2147/
NDT.S63904
10. Correll CU, Solmi M, Veronese N, et al.
Prevalence, incidence and mortality from
cardiovascular disease in patients with pooled and
specific severe mental illness: a large-scale
meta-analysis of 3,211,768 patients and 113,383,368
controls. World Psychiatry. 2017;16(2):163-180. doi:
10.1002/wps.20420
11. Daskalopoulou M, George J, Walters K, et al.
Depression as a risk factor for the initial
presentation of twelve cardiac, cerebrovascular,
and peripheral arterial diseases: data linkage study
of 1.9 million women and men. PLoS One. 2016;11
(4):e0153838. doi:10.1371/journal.pone.0153838
12. Liu N, Pan XF, Yu C, et al; China Kadoorie
Biobank Collaborative Group. Association of major
depression with risk of ischemic heart disease in a
mega-cohort of Chinese adults: the China Kadoorie
Biobank Study. J Am Heart Assoc. 2016;5(12):
e004687. doi:10.1161/JAHA.116.004687
13. Russ TC, Stamatakis E, Hamer M, Starr JM,
Kivimäki M, Batty GD. Association between
psychological distress and mortality: individual
participant pooled analysis of 10 prospective cohort
studies. BMJ. 2012;345:e4933. doi:10.1136/bmj.
e4933
14. Lichtman JH, Froelicher ES, Blumenthal JA,
et al; American Heart Association Statistics
Committee of the Council on Epidemiology and
Prevention and the Council on Cardiovascular and
Stroke Nursing. Depression as a risk factor for poor
prognosis among patients with acute coronary
syndrome: systematic review and
recommendations: a scientific statement from the
American Heart Association. Circulation. 2014;129
(12):1350-1369. doi:10.1161/CIR.
0000000000000019
15. Vaccarino V, Badimon L, Bremner JD, et al; ESC
Scientific Document Group Reviewers. Depression
and coronary heart disease: 2018 position paper of
the ESC working group on coronary
pathophysiology and microcirculation. Eur Heart J.
2020;41(17):1687-1696. doi:10.1093/eurheartj/ehy913
16. Danesh J, Erqou S, Walker M, et al; Emerging
Risk Factors Collaboration. The Emerging Risk
Factors Collaboration: analysis of individual data on
lipid, inflammatory and other markers in over 1.1
million participants in 104 prospective studies of
cardiovascular diseases. Eur J Epidemiol. 2007;22
(12):839-869. doi:10.1007/s10654-007-9165-7
17. Sudlow C, Gallacher J, Allen N, et al. UK
Biobank: an open access resource for identifying
the causes of a wide range of complex diseases of
middle and old age. PLoS Med. 2015;12(3):e1001779.
doi:10.1371/journal.pmed.1001779
18. Radloff LS. The CES-D scale: a self-report
depression scale for research in the general
population. Appl Psychol Meas. 1977;1(3):385-401.
doi:10.1177/014662167700100306
19. Kohout FJ, Berkman LF, Evans DA,
Cornoni-Huntley J. Two shorter forms of the CES-D
(Center for Epidemiological Studies Depression)
depression symptoms index. J Aging Health. 1993;5
(2):179-193. doi:10.1177/089826439300500202
20. Søgaard AJ, Bjelland I, Tell GS, Røysamb E.
A comparison of the CONOR Mental Health Index to
the HSCL-10 and HADS. Norsk Epidemiol. 2003;13
(2):279-284.
21. Kroenke K, Spitzer RL, Williams JBW. The
Patient Health Questionnaire-2: validity of a
two-item depression screener. Med Care. 2003;41
(11):1284-1292. doi:10.1097/01.MLR.0000093487.
78664.3C
22. Thompson S, Kaptoge S, White I, Wood A, Perry
P, Danesh J; Emerging Risk Factors Collaboration.
Statistical methods for the time-to-event analysis of
individual participant data from multiple
epidemiological studies. Int J Epidemiol. 2010;39
(5):1345-1359. doi:10.1093/ije/dyq063
23. Jackson D, White IR, Thompson SG. Extending
DerSimonian and Laird’s methodology to perform
multivariate random effects meta-analyses. Stat Med.
2010;29(12):1282-1297. doi:10.1002/sim.3602
24. Plummer M. Improved estimates of floating
absolute risk. Stat Med. 2004;23(1):93-104. doi:10.
1002/sim.1485
25. Royston P, Ambler G, Sauerbrei W. The use of
fractional polynomials to model continuous risk
variables in epidemiology. Int J Epidemiol. 1999;28
(5):964-974. doi:10.1093/ije/28.5.964
26. Higgins JP, Thompson SG, Deeks JJ,
Altman DG. Measuring inconsistency in
meta-analyses. BMJ. 2003;327(7414):557-560.
doi:10.1136/bmj.327.7414.557
27. Smith DJ, Nicholl BI, Cullen B, et al. Prevalence
and characteristics of probable major depression
and bipolar disorder within UK Biobank:
cross-sectional study of 172,751 participants. PLoS
One. 2013;8(11):e75362. doi:10.1371/journal.pone.
0075362
28. Smith GD, Ebrahim S. “Mendelian
randomization”: can genetic epidemiology
contribute to understanding environmental
determinants of disease? Int J Epidemiol. 2003;32
(1):1-22. doi:10.1093/ije/dyg070
29. Sutin AR, Terracciano A, Milaneschi Y, An Y,
Ferrucci L, Zonderman AB. The trajectory of
depressive symptoms across the adult life span.
JAMA Psychiatry. 2013;70(8):803-811. doi:10.1001/
jamapsychiatry.2013.193
30. Davey A, Halverson CF Jr, Zonderman AB,
Costa PT Jr. Change in depressive symptoms in the
Baltimore longitudinal study of aging. J Gerontol B
Psychol Sci Soc Sci. 2004;59(6):270-277. doi:10.
1093/geronb/59.6.P270
Association Between Depressive Symptoms and Incident Cardiovascular Diseases Original Investigation Research
jama.com (Reprinted) JAMA December 15, 2020 Volume 324, Number 23 2405
© 2020 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a Cambridge University Library User  on 01/12/2021
